Jiangsu Vcare PharmaTech Submits NDA to US FDA for Vicagrel, a P2Y12 Receptor Antagonist

Jiangsu Vcare PharmaTech Co., Ltd, a Chinese pharmaceutical company, has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its vicagrel, a P2Y12 receptor antagonist. The drug is proposed for the treatment of acute coronary syndrome (ACS), ischemic stroke, and thrombotic cardiovascular and diagnosed peripheral arterial disease.

Established in 2010, Vcare Pharma has an impressive pipeline with five Category 1 innovative drug programs under clinical development. These include vicagrel, VC004 capsules which are in pivotal Phase II trials in China, VC004 gel, VC005 tablets in Phase II stage in China, and VC005 gel in Phase I in China. The company’s therapeutic focus spans across cardiovascular and cerebrovascular diseases, oncology, and autoimmune diseases.- Flcube.com

Fineline Info & Tech